Welcome to our dedicated page for Structure Therapeutics ADR news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics ADR stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity. News about Structure Therapeutics often centers on progress in its GPCR-targeted pipeline, including clinical trial updates, preclinical data presentations, and capital markets activities related to its development programs.
Investors and observers following GPCR news can expect regular updates on aleniglipron (GSBR-1290), the company’s investigational once-daily oral small molecule GLP-1 receptor agonist. Press releases have covered topline Phase 2b and exploratory study results in people living with obesity or overweight with weight-related comorbidities, details of the ACCESS and ACCESS II clinical programs, body composition and maintenance switching studies, and plans for potential Phase 3 development.
Another frequent news theme is the company’s amylin receptor agonist portfolio, including ACCG-2671 and ACCG-3535. Structure Therapeutics has announced initiation of a first-in-human Phase 1 clinical study of ACCG-2671 for obesity, as well as late-breaking poster presentations showing preclinical data on weight loss and combination effects with GLP-1 receptor agonists. Updates also include disclosures about its broader oral metabolic franchise, such as GIPR, GCGR and APJR programs, and the LPA1R program for idiopathic pulmonary fibrosis.
In addition, GPCR news items include quarterly financial results, business updates, and information on public offerings of American Depositary Shares and pre-funded warrants conducted under an automatic shelf registration statement on Form S-3. Coverage may also highlight participation in healthcare investor conferences and outcomes of annual shareholder meetings. Readers interested in Structure Therapeutics news can use this page to track clinical milestones, financing transactions, and other corporate developments disclosed through press releases and SEC-related announcements.
Structure Therapeutics Inc. (NASDAQ: GPCR) has announced key leadership changes to drive its next phase of development. Blai Coll, M.D., Ph.D., has been promoted to Chief Medical Officer, replacing Mark Bach, M.D., Ph.D., effective September 18, 2024. Dr. Coll has been leading the GSBR-1290 program, an oral small molecule GLP-1 agonist for obesity, set to enter Phase 2b clinical trials in Q4 2024.
Additionally, Ashley Hall, J.D., has been appointed as Chief Development Officer, a new position overseeing clinical development operations, project management, regulatory affairs, and quality assurance. These appointments aim to strengthen the company's position as it advances its clinical programs, including the development of an oral amylin compound.
Structure Therapeutics Inc. (NASDAQ: GPCR) has appointed Angus C. Russell to its board of directors. Mr. Russell, former CEO of Shire plc, brings over 30 years of experience in the global biopharmaceutical industry. This appointment comes as Structure prepares to advance its oral small molecule GLP-1 agonist, GSBR-1290, into late-stage clinical development for obesity. CEO Raymond Stevens highlighted Russell's expertise in strategy, finance, operations, and commercialization as valuable assets for the company's growth. Russell expressed enthusiasm for Structure's potential in the obesity market, particularly with GSBR-1290 and its pipeline of oral small molecule therapeutics.
Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company focusing on novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on Thursday, September 5 at 10:00 a.m. EDT
2. Cantor Fitzgerald Global Healthcare Conference 2024: Fireside chat on Thursday, September 19 at 9:10 a.m. EDT
Live and archived webcasts of both fireside chats will be available on the company's website, with replays accessible for 90 days after the events.
Structure Therapeutics (NASDAQ: GPCR) reported Q2 2024 financial results and recent highlights. Key points include:
1. GSBR-1290 Phase 2b obesity study on track for Q4 2024 initiation.
2. Oral small molecule amylin receptor agonist development candidate expected in Q4 2024.
3. Strong financial position with $927.1 million cash balance, funding operations through at least 2027.
4. Q2 2024 R&D expenses increased to $22.1 million from $19.4 million in Q2 2023.
5. Q2 2024 G&A expenses rose to $11.3 million from $6.6 million in Q2 2023.
6. Net loss for Q2 2024 was $26.0 million, compared to $23.3 million in Q2 2023.
7. GSBR-1290 Phase 2a results showed 6.2% placebo-adjusted mean weight loss at 12 weeks.
Structure Therapeutics (NASDAQ: GPCR) announced the closing of its upsized public offering of 10,427,017 American depositary shares (ADSs), each representing three ordinary shares, at $52.50 per ADS. The offering, which included the full exercise of the underwriters' option to purchase an additional 1,360,045 ADSs, generated gross proceeds of around $547.4 million. The proceeds are subject to underwriting discounts, commissions, and offering expenses. The offering was managed by Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets. The registration statements for the securities became effective on June 5, 2024.
Structure Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: GPCR), announced the pricing of its upsized public offering. The company is set to offer 9,066,972 American Depositary Shares (ADS) at $52.50 each, aiming for gross proceeds of approximately $476 million before deductions. An additional 1,360,045 ADSs may be purchased by underwriters within 30 days. The offering, managed by major financial institutions including Goldman Sachs and Morgan Stanley, will close on June 7, 2024, contingent on standard conditions.
Structure Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: GPCR), has filed a Form S-1 registration statement with the SEC for a proposed public offering of 8,000,000 American depositary shares (ADSs). Each ADS represents three ordinary shares. The company may also offer pre-funded warrants in lieu of ADSs. The price per pre-funded warrant will be the ADS price minus $0.0001. The underwriters have a 30-day option to purchase up to an additional 1,200,000 ADSs. The offering's completion depends on market conditions and other factors. Joint book-running managers include Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets.
Structure Therapeutics announced positive topline data from its Phase 2a study and capsule to tablet PK study for its oral GLP-1 receptor agonist, GSBR-1290. The Phase 2a study showed a statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks, while the capsule to tablet PK study achieved up to a 6.9% weight loss. GSBR-1290 demonstrated favorable safety and tolerability with low discontinuation rates due to adverse events.
The company plans to start a 36-week Phase 2b study in the fourth quarter of 2024, following an IND submission to the FDA in the third quarter. The new study will use the tablet formulation and involve approximately 300 participants.
These results underscore the potential of GSBR-1290 as a treatment for obesity, with benefits including once-daily dosing and favorable safety profiles. Future development plans include exploring higher doses and combination therapies.
Structure Therapeutics Inc., a biopharmaceutical company, reported financial results for Q1 2024, highlighting upcoming milestones such as data release for obesity drug GSBR-1290 and plans for Phase 2b study. The company aims to address obesity epidemic with its oral small molecule GLP-1 receptor agonist. Positive financial highlights include a cash position of $436.4 million, funding projected operations through 2026.
Summary not available.